The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Mark E. Williams

Renal Unit

Joslin Diabetes Center

Boston

MA 02215

USA

[email]@*.harvard.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Renal Unit, Joslin Diabetes Center, Boston, MA 02215, USA. 2003 - 2010

References

  1. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Williams, M.E., Lacson, E., Wang, W., Lazarus, J.M., Hakim, R. Clin. J. Am. Soc. Nephrol (2010) [Pubmed]
  2. Management of diabetes in dialysis patients. Williams, M.E. Curr. Diab. Rep. (2009) [Pubmed]
  3. Chronic kidney disease/bone and mineral metabolism: the imperfect storm. Williams, M.E. Semin. Nephrol. (2009) [Pubmed]
  4. Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the USA. Williams, M.E., Lacson, E., Teng, M., Hakim, R.M., Lazarus, J.M. Am. J. Nephrol. (2009) [Pubmed]
  5. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Williams, M.E., Bolton, W.K., Khalifah, R.G., Degenhardt, T.P., Schotzinger, R.J., McGill, J.B. Am. J. Nephrol. (2007) [Pubmed]
  6. The ESRD uninsured matter. Williams, M.E. Advances. Chronic. Kidney. Disease (2007) [Pubmed]
  7. Internet organ solicitation, explained. Williams, M.E. Advances. Chronic. Kidney. Disease (2006) [Pubmed]
  8. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Williams, M.E., Lacson, E., Teng, M., Ofsthun, N., Lazarus, J.M. Kidney Int. (2006) [Pubmed]
  9. New potential agents in treating diabetic kidney disease: the fourth act. Williams, M.E. Drugs (2006) [Pubmed]
  10. Coronary revascularization in diabetic chronic kidney disease/end-stage renal disease: a nephrologist's perspective. Williams, M.E. Clinical J. American Society Nephrology : Cjasn (2006) [Pubmed]
  11. The involuntarily discharged dialysis patient: conflict (of interest) with providers. Williams, M.E., Kitsen, J. Advances. Chronic. Kidney. Disease (2005) [Pubmed]
  12. Diabetic nephropathy: the proteinuria hypothesis. Williams, M.E. Am. J. Nephrol. (2005) [Pubmed]
  13. Promise or peril? Impact of the Medicare drug benefit on the ESRD population. Williams, M.E. Advances. Chronic. Kidney. Disease (2004) [Pubmed]
  14. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Williams, M.E. Curr. Diab. Rep. (2004) [Pubmed]
  15. New therapies for advanced glycation end product nephrotoxicity: current challenges. Williams, M.E. Am. J. Kidney Dis. (2003) [Pubmed]
 
WikiGenes - Universities